Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:IMVT NASDAQ:SLNO NYSE:SNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.97+5.4%$0.98$0.69▼$1.80$31.55M-2.56264,476 shs308,989 shsIMVTImmunovant$17.29+2.4%$15.39$12.72▼$34.47$2.96B0.631.22 million shs1.47 million shsSLNOSoleno Therapeutics$88.49+3.8%$78.33$41.50▼$90.32$4.46B-2.63795,364 shs1.49 million shsSNNSmith & Nephew SNATS$30.74+3.3%$29.19$23.69▼$31.72$13.46B0.69861,421 shs3.96 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-1.00%-1.86%+15.00%-22.03%-19.30%IMVTImmunovant+2.86%+4.58%+0.72%+13.36%-38.92%SLNOSoleno Therapeutics-0.01%+3.18%+12.91%+34.76%+101.04%SNNSmith & Nephew SNATS-0.70%-2.78%-1.78%+15.09%+9.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys3.7891 of 5 stars3.55.00.00.03.62.50.6IMVTImmunovant1.3923 of 5 stars3.52.00.00.00.01.70.0SLNOSoleno Therapeutics4.4402 of 5 stars3.52.00.04.63.22.50.6SNNSmith & Nephew SNATS3.5895 of 5 stars1.05.02.50.02.70.04.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67793.47% UpsideIMVTImmunovant 2.90Moderate Buy$38.33121.71% UpsideSLNOSoleno Therapeutics 3.09Buy$107.1021.03% UpsideSNNSmith & Nephew SNATS 2.00Hold$28.00-8.91% DownsideCurrent Analyst Ratings BreakdownLatest SLNO, FEMY, IMVT, and SNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.005/1/2025SNNSmith & Nephew SNATSCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$27.00 ➝ $28.004/25/2025SNNSmith & Nephew SNATSHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/25/2025SNNSmith & Nephew SNATSHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M19.36N/AN/A$0.10 per share9.70IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ASNNSmith & Nephew SNATS$5.81B2.32$3.24 per share9.49$12.04 per share2.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)SNNSmith & Nephew SNATS$412M$2.1614.2315.370.92N/AN/AN/A8/5/2025 (Estimated)Latest SLNO, FEMY, IMVT, and SNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$0.892.90%N/A41.20%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.020.930.54IMVTImmunovantN/A11.1611.16SLNOSoleno Therapeutics0.2119.6419.64SNNSmith & Nephew SNATS0.622.891.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%IMVTImmunovant47.08%SLNOSoleno Therapeutics97.42%SNNSmith & Nephew SNATS25.64%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%IMVTImmunovant5.90%SLNOSoleno Therapeutics6.40%SNNSmith & Nephew SNATS1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.53 million22.60 millionNot OptionableIMVTImmunovant120170.92 million160.84 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableSNNSmith & Nephew SNATS17,349437.97 million433.59 millionOptionableSLNO, FEMY, IMVT, and SNN HeadlinesRecent News About These CompaniesCallan Capital LLC Takes Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)July 9 at 5:36 AM | marketbeat.comSmith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Rating of "Hold" from AnalystsJuly 9 at 3:37 AM | marketbeat.comSmith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless optionJuly 7 at 10:00 AM | globenewswire.comSmith & Nephew SNATS, Inc. (NYSE:SNN) Shares Acquired by Oppenheimer Asset Management Inc.June 28, 2025 | marketbeat.comSNN Expands Orthopedic Portfolio With Advanced Tibia Nailing SystemJune 26, 2025 | zacks.comSNN vs. GEHC: Which Stock Is the Better Value Option?June 25, 2025 | zacks.comIs Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?June 25, 2025 | zacks.comSmith & Nephew SNATS (NYSE:SNN) Sees Unusually-High Trading Volume - Time to Buy?June 24, 2025 | marketbeat.comSmith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fracturesJune 24, 2025 | globenewswire.comScharf Investments LLC Sells 555,004 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)June 23, 2025 | marketbeat.comAjay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy OfficerJune 23, 2025 | globenewswire.comSmith+Nephew Stock May Gain From Strategic Deal With Standard HealthJune 20, 2025 | zacks.comSmith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UKJune 18, 2025 | globenewswire.comSmith & Nephew plc (NYSE:SNN) Sees Significant Increase in Short InterestJune 16, 2025 | marketbeat.comLorne Steinberg Wealth Management Inc. Boosts Position in Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comPark Avenue Securities LLC Acquires Shares of 9,206 Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Given Average Recommendation of "Hold" by BrokeragesJune 14, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Shares Purchased by GAMMA Investing LLCJune 13, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes Position in Smith & Nephew plc (NYSE:SNN)June 10, 2025 | marketbeat.comNew medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatilityJune 9, 2025 | globenewswire.comSmith & Nephew (SN) Receives a Buy from CitiJune 7, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLNO, FEMY, IMVT, and SNN Company DescriptionsFemasys NASDAQ:FEMY$0.97 +0.05 (+5.43%) Closing price 04:00 PM EasternExtended Trading$0.97 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Immunovant NASDAQ:IMVT$17.29 +0.40 (+2.37%) Closing price 04:00 PM EasternExtended Trading$17.82 +0.53 (+3.04%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Soleno Therapeutics NASDAQ:SLNO$88.49 +3.23 (+3.79%) Closing price 04:00 PM EasternExtended Trading$88.49 0.00 (0.00%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Smith & Nephew SNATS NYSE:SNN$30.74 +0.97 (+3.26%) As of 03:57 PM EasternSmith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
